The incidence of NHL has increased dramatically in recent years, making it the second fastest growing form of cancer. Without successful treatment the average life expectancy of patients is one to six years. Scientists have actively searched for other therapies that are safe, effective and might improve survival rates. The researchers studied 400 previously untreated patients with aggressive NHL, aged 60 or older. Results from an interim analysis of 328 patients show that those treated with R-CHOP experienced a significant improvement versus CHOP alone.
Physicians have a higher chance of curing patients in complete remission.
Combining the rituximab antibody with CHOP did not cause additional treatment-related side effects. The absence of increased toxicity is especially important for elderly patients who are often more sensitive to the side effects of chemotherapy. Ltd. All rights reserved. The material available at this site is for educational purposes only and is NOT intended for any diagnostic, clinically related, or other purpose. Carden Jennings Publishing Co., Ltd., assumes no responsibility for any use or misuse of this material and makes no warranty or representation of any kind with respect to the material available at this site.